Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Measurement Tools for Patients with SSc and GERD

J Rheumatol; 2019 Jan; McMahan, Frech, et al

The UCLA GI Tract (UCLA GIT) Questionnaire 2.0 Reflux scale, Patient-Reported Outcomes Measurement Information System (PROMIS) Reflux scale, and Quality of Life in Reflux and Dyspepsia (QOLRAD) questionnaire all proved sensitive to change and therefore, can be included in clinical trials. This according to a recent study that sought to determine whether these 3 patient-reported outcome measures are sensitive to identifying changes in gastrointestinal (GI) symptoms following therapeutic intervention in participants with systemic sclerosis (SSc) and gastroesophageal reflux disease (GERD). Participants (n=116) with active GERD were recruited during clinical visits at 6 international SSc centers. Researchers found:

  • The UCLA GIT 2.0 Reflux scale and PROMIS Reflux scale had a significant correlation at baseline (0.61), and both instruments correlated with the QOLRAD domains (−0.56 to −0.71).
  • For those who had the 3 measures administered over 2 time points (n=57) and were classified as improved, the effect size was large for the UCLA GIT 2.0 and PROMIS Reflux scale, and moderate to large across all QOLRAD domains.


McMahan ZH, Frech T, Berrocal V, et al. Longitudinal assessment of patient-reported outcome measures in systemic sclerosis patients with gastroesophageal reflux disease—Scleroderma Clinical Trials Consortium. J Rheumatol. 2019;46(1):78-84. doi:10.3899/jrheum.180004.

This Week's Must Reads

Treating Patients with RA Who Have Cancer, Arthritis Care Res; ePub 2019 Mar 1; Lopez-Olivo, et al

Impact, Timing of Smoking Cessation on RA Risk, Arthritis Care Res; ePub 2019 Feb 21; Liu, et al

HLA-DRB1 Haplotypes and RA Disease Outcomes, J Rheumatol; ePub 2019 Mar 1; Zhao, Mauer, et al

Myocardial Inflammation and Disease Activity in RA , Arthritis Rheumatol; ePub 2019 Feb 28; Amigues, et al

Multibiomarker Disease Activity Testing for RA , J Rheumatol; 2019 Mar; Curtis, Xie, Yang, et al

Must Reads in Lupus & Connective Tissue Diseases

African American Scleroderma Patients and Mortality, Arthritis Care Res; ePub 2019 Mar 1; Moore, et al

Inflammatory Arthritis a Risk for THA Complications , J Arthroplasty; ePub 2019 Feb 18; Richardson, et al

Remission/Low Disease Activity Protective in SLE , Lupus; ePub 2019 Jan 24; Alarcón, Ugarte-Gil, et al

List of medications linked to drug-induced lupus expands, Arnaud L et al. Ann Rheum Dis. 2019 Feb 4. doi: 10.1136/annrheumdis-2018-214598